Soligenix Inc (Nasdaq: SNGX), a late-stage biopharmaceutical company, has completed enrolment of its patients in its phase three DOM-INNATE study for SGX942 (dusquetide) intended to treat oral mucositis in head and neck cancer patients, it was reported on Wednesday.
The study enrolled 268 subjects based on positive interim analysis that included an assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee. The top-line results of the study are likely to be revealed in the fourth quarter of 2020.
The product is a novel, first-in-class, Innate Defense Regulator that modulates inflammation and improves the innate immune system's anti-infective and tissue-healing pathways.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval